News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center

Articles by Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center

Future Directions for Treatment of TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Phase 3 ASCENT Trial in mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Sequencing Therapies for mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Standard of Care for BRCA+ mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Testing for PD-L1 Expression in mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

KEYNOTE-355 Trial in mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Standard of Care for Metastatic TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Current Trials for Treatment of Early Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Emerging Data on Biomarkers in ES TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

ICI-Based Therapy in TNBC: Immune-Related Adverse Events

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Early Stage TNBC: Phase 3 IMpassion031 Study

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Key Trials in ICI-Based Therapy for Early Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Role of pCR in Early Stage TNBC Management

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Standard of Care for Early-Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Latest Updated Articles

Testing for PD-L1 Expression in mTNBC
Published: October 23rd 2020 | Updated:
ICI-Based Therapy in TNBC: Immune-Related Adverse Events
Published: October 23rd 2020 | Updated:
Sequencing Therapies for mTNBC
Published: October 23rd 2020 | Updated:
Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC
Published: October 23rd 2020 | Updated:
Standard of Care for Metastatic TNBC
Published: October 23rd 2020 | Updated:
Future Directions for Treatment of TNBC
Published: October 23rd 2020 | Updated:

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma